- Home
- MELI vs GILD Comparison
MELI vs GILD Comparison
Compare MELI & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MELI
- GILD
- Stock Information
- Founded
- MELI 1999
- GILD 1987
- Country
- MELI Uruguay
- GILD United States
- Employees
- MELI N/A
- GILD N/A
- Industry
- MELI Catalog/Specialty Distribution
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MELI Consumer Discretionary
- GILD Health Care
- Exchange
- MELI Nasdaq
- GILD Nasdaq
- Market Cap
- MELI 124.4B
- GILD 139.6B
- IPO Year
- MELI 2007
- GILD 1992
- Fundamental
- Price
- MELI $2,165.13
- GILD $115.85
- Analyst Decision
- MELI Strong Buy
- GILD Buy
- Analyst Count
- MELI 19
- GILD 23
- Target Price
- MELI $2,821.58
- GILD $116.36
- AVG Volume (30 Days)
- MELI 477.5K
- GILD 7.7M
- Earning Date
- MELI 11-05-2025
- GILD 11-05-2025
- Dividend Yield
- MELI N/A
- GILD 2.71%
- EPS Growth
- MELI 46.70
- GILD 496.80
- EPS
- MELI 40.49
- GILD 5.01
- Revenue
- MELI $24,096,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- MELI $38.44
- GILD $2.07
- Revenue Next Year
- MELI $26.32
- GILD $3.95
- P/E Ratio
- MELI $54.03
- GILD $23.30
- Revenue Growth
- MELI 35.81
- GILD 3.81
- 52 Week Low
- MELI $1,646.00
- GILD $84.17
- 52 Week High
- MELI $2,645.22
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- MELI 33.62
- GILD 56.56
- Support Level
- MELI $2,116.00
- GILD $108.46
- Resistance Level
- MELI $2,548.50
- GILD $117.00
- Average True Range (ATR)
- MELI 79.40
- GILD 3.05
- MACD
- MELI -35.40
- GILD 0.25
- Stochastic Oscillator
- MELI 10.40
- GILD 82.44
About MELI MercadoLibre Inc.
MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).